002210 — Dongsung Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩91bn
- KR₩140bn
- KR₩88bn
Annual income statement for Dongsung Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 87,800 | 84,408 | 93,328 | 88,594 | 88,448 |
| Cost of Revenue | |||||
| Gross Profit | 34,149 | 33,544 | 42,055 | 41,370 | 38,884 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 91,699 | 89,741 | 96,438 | 88,872 | 95,078 |
| Operating Profit | -3,899 | -5,333 | -3,110 | -278 | -6,630 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10,806 | -4,379 | -1,851 | -866 | -7,656 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14,079 | -4,313 | -2,122 | -2,074 | -7,253 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14,079 | -4,313 | -2,122 | -2,074 | -7,253 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14,079 | -4,313 | -2,122 | -2,074 | -7,253 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -594 | -185 | -92.2 | -65.8 | -319 |
| Dividends per Share |